Persistent vaccination effect of GRAZAX® after completion of treatment

Breakthrough: Results from the fourth year in a long-term clinical study prove
the disease modifying effect of GRAZAX®. For the first time ever, it is
documented that the positive clinical effect of the tablet vaccine persists
after completion of treatment. 

Today, ALK announces main results from the first follow-up year in a long-term
study (GT-08) with GRAZAX®, the company's tablet-based vaccine against grass
pollen allergy. The clinical study documents that the effect of GRAZAX®
persists following completion of the recommended three-year treatment regimen.
Furthermore, blood samples from patients show a persistent, positive effect on
the immune system indicating a lasting tolerance to grass pollen. 

During the first year after completion of treatment, GRAZAX® continues to
provide statistically significant reductions in both hay fever symptoms and the
use of symptom-relieving medication. 

In the follow-up year, hay fever symptoms were reduced by 31% while the use of
symptom-relieving medication was reduced by 52%. The reduction of symptoms and
use of medication is measured as median values relative to a control group in
which patients had unrestricted access to symptom-relieving medication. 
 
The patients in the study have adhered to the recommended three-year GRAZAX®
treatment regimen and completed treatment in the autumn of 2007. The
above-mentioned results cover the 2008 pollen season, the first season in which
the patients did not receive active treatment with GRAZAX®. 

The fourth-year results represent a major breakthrough, since ALK is the first
company ever to document a persistent disease modifying vaccination effect of a
tablet-based allergy vaccine. Patients cannot obtain such a persistent
vaccination effect with traditional symptom-relieving allergy medication. 


ALK-Abelló A/S

Jens Bager
President and CEO

ALK will host a conference call today at 2.30 p.m. (CET) at which Jens Bager,
President and CEO and Executive Vice President of R&D, Henrik Jacobi will
review the results. Danish participants must call in on tel +45 7026 5040
before 2.25 p.m. (CET), and international participants must call in on tel +44
208 817 9301 before 2.25 p.m. (CET). The conference call will also be webcast
on our website www.alk-abello.com, where the related presentation will be
available shortly before the conference call begins. 


For further information please contact:
Jens Bager, President and CEO, tel. +45 4575 7576

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551